Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  peginterferon alfa-2b
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 26 for your search:
Start Over
Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC
Phase: Phase IV
Type: Treatment
Status: Closed
Age: 25 to 75
Sponsor: Other
Protocol IDs: O2006-415, NCT00375661
Phase II/III Randomized Study of SCH 54031 (Polyethylene Glycol Interferon alfa-2b) Versus Interferon alfa-2b in Patients With Newly Diagnosed Chronic Phase Myelogenous Leukemia (Summary Last Modified 01/2000)
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: SPRI-C98-026, SPRI-C98-026-054, SPRI-I98-026
Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma
Phase: Phase III
Type: Treatment
Status: Closed
Age: 5 to 40 at diagnostic biopsy
Sponsor: NCI, Other
Protocol IDs: AOST0331, NCI-2009-01066, EUDRACT-2004-000242-20, MRC-EURAMOS1, MRC-BO08, ISRCTN67613327, EU-20530, CDR0000438714, COG-AOST0331, U10CA098543, NCT00134030
Feasibility of the Combination of Chemotherapy (Carbo/Caelyx or Carbo/Doxorubicin) With Tocilizumab (mAb IL-6R) and Peg-Intron in Patients With Recurrent Ovarian Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: PITCH trial, NCT01637532
Chemo-immunotherapy (Gemcitabine, Interferon-alpha 2b and p53 SLP) in Patients With Platinum-resistant Ovarian Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CHIP trial, 2010-023124-24, NCT01639885
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000258114, E2602, U10CA021115, ECOG-2602, NCT00049530
Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: 030002, 03-C-0002, NCI-03-C-0002, NABTC-0201, NCT00052650, NCT00047879
Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02519, MDA-ID-02063, N01CM62202, CDR0000271225, NCI-4772, 4772, NCT00055809
PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000378049, MUSC-100614, CELGENE-MUSC-100614, MUSC-HR-10423, NCT00090870
Phase II Study of Pegylated-Interferon alfa-2b and Rituximab in Patients With Advanced Indolent Non-Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-02033A
PEG-interferon Alfa-2b in Treating Patients With Stage II, Stage III, or Stage IV Head and Neck Cancer That Can Be Removed By Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000441020, MDA-ID-01450, ID01-450, NCT00276523
PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000445593, P30CA022453, WSU-C-2257, WSU-HIC-120900M01-FB, NCT00238329
Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000540598, P30CA093373, CCC-PHII-40, ZENECA-AZ1839US/0227, UCD-200412338-4, UCD-ZD1839, PHII-40, NCT00467077
Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2005-0143, NCI-2010-00855, NCT00525031
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 21 and under
Sponsor: Other
Protocol IDs: MEL06, NCI-2011-01192, NCT00539591
Combined Treatment of Sorafenib and Pegylated Interferon a2b in Stage IV Metastatic Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: DeCOG SoraPeg 2007, EudraCT 2007-001918-16, NCT00623402
A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 19 and over
Sponsor: Other
Protocol IDs: USA-MCI-01, IND# 13647, NCT00746746
Combination of Dasatinib and Peg-Interferon Alpha 2b in First Line for Chronic Myeloid Leukemia in Chronic Phase
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 to 65
Sponsor: Other
Protocol IDs: DASA-PegIFN, NCT01872442
A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 4031-400, NCT02155322
Temozolomide Plus PEG-Interferon Alfa-2B in Treating Patients With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000068523, P30CA023108, DMS-0010, NCI-G01-1924, NCT00014261
High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: P04831, NCT00457418
Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2006-0816, NCI-2012-01652, NCT00861406
Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma
Phase: Phase I
Type: Treatment
Status: Closed
Age: 16 and over
Sponsor: Other
Protocol IDs: MCC-16755, NCT01496807
A Study of Pegylated Interferon Alfa-2b as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (P08556)
Phase: Phase I
Type: Treatment
Status: Closed
Age: 20 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: P08556, MK-4031-370, 132228, NCT01636960
Start Over